Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
2
item.page.dc.date.issued
2023-01-01
item.page.dc.type
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85160694959
item.page.oaire.citation.title
Economic Evaluation in Genomic and Precision Medicine
item.page.oaire.citation.startPage
71
item.page.oaire.citation.endPage
86
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Economic Evaluation in Genomic and Precision Medicine (2023) , 71-86
punsarn.item.page.citation
Yuliwulandari R., Chaikledkaew U., Prayuni K., Zahroh H., Mahasirimongkol S., Turongkaravee S., Jittikoon J., Wattanapokayakit S., Patrinos G.P. Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions. Economic Evaluation in Genomic and Precision Medicine (2023) , 71-86. 86. doi:10.1016/B978-0-12-813382-8.00003-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82983
item.page.dc.title
Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.